36070367|t|A tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse model of Alzheimer's disease.
36070367|a|Triggering receptor expressed on myeloid cells 2 (TREM2) plays crucial roles in Alzheimer's disease (AD) by regulating microglia migration toward, and phagocytosis of oligomeric amyloid-beta (oAbeta) and amyloid plaques. Studies in rodent models of AD have shown that mice with increased TREM2 expression have reduced amyloid pathology. Here, we identified a TREM2 agonist monoclonal Ab (Ab18) by panning a phage-displayed single-chain variable fragment Ab library. By engineering the bivalent immunoglobulin G1 (IgG1) to tetra-variable domain immunoglobulin (TVD-Ig), we further increased the TREM2 activation by 100-fold. Stronger TREM2 activation led to enhanced microglia phagocytosis of the oAbeta-lipid complex, migration toward oAbeta, and improved microglia survival in vitro. Mechanistic studies showed increased TREM2 clustering on microglia by the tetravalent Ab18 TVD-Ig without altering microglial TREM2 amount. An engineered bispecific Ab targeting TREM2 and transferrin receptor (TfR; Ab18 TVD-Ig/alphaTfR) improved Ab brain entry by more than 10-fold with a broad brain parenchyma distribution. Weekly treatment of 5XFAD mice (a model of AD) with Ab18 TVD-Ig/alphaTfR showed a considerable reduction of amyloid burden with increased microglia migration to and phagocytosis of amyloid plaques, improved synaptic and neuronal marker intensity, improved cognitive functions, reduced endogenous tau hyperphosphorylation, and decreased phosphorylated neurofilament H immunostaining. This study demonstrated the feasibility of engineering multivalent TREM2 agonistic Ab coupled with TfR-mediated brain delivery to enhance microglia functions and reduce amyloid pathology in vitro and in vivo. This Ab engineering approach enables the development of effective TREM2-targeting therapies for AD.
36070367	14	19	TREM2	Gene	83433
36070367	47	54	amyloid	Disease	MESH:C000718787
36070367	70	75	mouse	Species	10090
36070367	85	104	Alzheimer's disease	Disease	MESH:D000544
36070367	106	154	Triggering receptor expressed on myeloid cells 2	Gene	83433
36070367	156	161	TREM2	Gene	83433
36070367	186	205	Alzheimer's disease	Disease	MESH:D000544
36070367	207	209	AD	Disease	MESH:D000544
36070367	273	296	oligomeric amyloid-beta	Chemical	-
36070367	298	304	oAbeta	Chemical	-
36070367	310	325	amyloid plaques	Disease	MESH:D058225
36070367	355	357	AD	Disease	MESH:D000544
36070367	374	378	mice	Species	10090
36070367	394	399	TREM2	Gene	83433
36070367	424	431	amyloid	Disease	MESH:C000718787
36070367	465	470	TREM2	Gene	83433
36070367	494	498	Ab18	Chemical	-
36070367	600	617	immunoglobulin G1	Gene	16017
36070367	619	623	IgG1	Gene	16017
36070367	700	705	TREM2	Gene	83433
36070367	739	744	TREM2	Gene	83433
36070367	802	808	oAbeta	Chemical	-
36070367	809	814	lipid	Chemical	MESH:D008055
36070367	841	847	oAbeta	Chemical	-
36070367	928	933	TREM2	Gene	83433
36070367	977	981	Ab18	Chemical	-
36070367	982	985	TVD	Chemical	-
36070367	1017	1022	TREM2	Gene	83433
36070367	1069	1074	TREM2	Gene	83433
36070367	1079	1099	transferrin receptor	Gene	22042
36070367	1101	1104	TfR	Gene	22042
36070367	1106	1110	Ab18	Chemical	-
36070367	1111	1114	TVD	Chemical	-
36070367	1243	1247	mice	Species	10090
36070367	1260	1262	AD	Disease	MESH:D000544
36070367	1269	1273	Ab18	Chemical	-
36070367	1274	1277	TVD	Chemical	-
36070367	1325	1332	amyloid	Disease	MESH:C000718787
36070367	1398	1413	amyloid plaques	Disease	MESH:D058225
36070367	1667	1672	TREM2	Gene	83433
36070367	1699	1702	TfR	Gene	22042
36070367	1769	1776	amyloid	Disease	MESH:C000718787
36070367	1875	1880	TREM2	Gene	83433
36070367	1905	1907	AD	Disease	MESH:D000544
36070367	Negative_Correlation	MESH:C000718787	83433
36070367	Association	22042	83433
36070367	Association	16017	83433
36070367	Association	MESH:D000544	83433
36070367	Association	MESH:D058225	83433

